Primer: CF PharmTech (2652 HK) - Aug 2026
CF PharmTech is a specialty pharmaceutical company focused on respiratory treatments, with a strong position in China's inhalation drug market....
91 Views
CF PharmTech (2652 HK): Synthetic Expert Call Transcript (03 Aug 2026)
CF PharmTech’s July 31, 2026 share placement—raising HK$294.81 million net at a 11.97% discount just nine months after its October 2025...
96 Views
CF PharmTech (2652 HK) Placement: Raising Fund to Feed R&D Amid Unutilized IPO Proceeds
CF PharmTech intends to place 22M H shares at the price of HK$13.82 per share. The placing price represents ~12% discount to the undisturbed...
134 Views
APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio
Innovent stuck $10.5B outlicensing deal with Pfizer. Olympus will acquire BioProtect. Eli Lilly is acquiring GC Bio’s US affiliate. Dong-A’s...
159 Views
No more insights